Single-center retrospective analysis of efficacy and safety of daratumumab plus dexamethasone for light chain amyloidosis nephropathy  

作　　者：薛韩 XUE Han(Kidney Dis Center,1st Affil Hosp,Zhejiang Univ Med Sch;Instit Nephrol,Zhejiang Univ,Zhejiang Prov Key Lab,Kidney Dis Prev&Treat Technol Res)

机构地区：[1]Kidney Dis Center,1st Affil Hosp,Zhejiang Univ Med Sch [2]Instit Nephrol,Zhejiang Univ,Zhejiang Prov Key Lab,Kidney Dis Prev & Treat Technol Res

出　　处：《China Medical Abstracts(Internal Medicine)》2024年第2期112-113,共2页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To analyze the efficacy and safety of daratumumab plus dexamethasone in the treatment of renal injury patients with light chain amyloidosis,and to provide clinical reference.Methods It was a single center retrospective observational study.The clinical data before and after daratumumab treatment of renal injury patients with light chain amyloidosis treated with daratumumab plus dexamethasone from December 2021 to August 2022 were retrospectively collected.

关 键 词：diagnosis ENDOSCOPIC treatment 

分 类 号：R692[医药卫生—泌尿科学]